The Governance Board of the Medicines Patent Pool:

1. Adopts the agenda for the 20 Governance Board meeting;
2. Adopts the minutes from the 19 Board meeting December 5, 2017;
3. Thank the services of Dr. Michel Manon as Board member and re-elects Dr. Anban Pillay, Dr. Charles Clift, Dr. Brian Tempest, Ms. Jayashree Watal and Ms. Claudia Chamas to serve an additional two-year term on the Board;
4. Thanks Dr. Shing Chang and Ms. Ludmila Maistat for their service on the MPP Expert Advisory Group. The Board, having considered the recommendations of MPP Management on individuals to serve in their place, agree to invite Mr. Giten Khwairakpam and Dr. Karine Lacombe to serve on the HCV sub-group of the Expert Advisory Group, and upon their acceptance, hereby appoints them to serve in this role;
5. The Board, after considering the recommendation of the Finance and Management Committee approves the:
   a. MPP Activity Report 2016 to be submitted to the Swiss Authorities;
   b. 2016 audit report and comprehensive report by Deloitte. The Board requests management that a partner from Deloitte meet with the Finance and Management Committee on an annual basis;
c. 2016 expenditure analysis and finds it to be an accurate and appropriate
depiction of the expenses throughout 2016;
d. 2017 budget submission and find the allocation of expenses appropriate
for the implementation of the UNITAID – MPP project plan. The
committee will work with management to update this budget as needed;
e. proposed changes to the Human Resources Policy;
f. Human Resources policy for the Indian Liaison office;
g. proposed changes to the MPP Travel and Expense Policy;
h. appointment of Dr. Brian Tempest as a member of the Finance and
Management Committee.

6. Approves of the Ethics & Compliance committee’s recommendation to proceed with the
search for a third party service provider to serve as Compliance Officer and requests
management to publish a call for proposals for a Compliance Officer on its website;

7. Approves of the changes made to Article 1 of the Ethics & Compliance committee Terms
of Reference;\(^1\) \(^2\)

8. Approves of the changes made to Article 3 of the Gifts Policy;\(^3\)

9. Recognizes that the EoI process and selection of sub-licensees is part of core business for
the Medicines Patent Pool and will work with management to strengthen the current
system. The Board, after having assessed the three-member pilot panel and the potential
outsourcing of the EoI process to a third party, decides to maintain the EoI process
internally. The Board agrees to establish a working group of Board Members to work with
the Executive Director and Business Development Director to strengthen its internal
procedure in evaluating sub-licensees, including a separation of tasks, the formation of
an appeals process and an annual audit of the EoI system;

10. Requests management develop a crisis communications plan and also to consider a
business continuation plan. The Board asks that a communication update is included in
the agenda for each Board meeting going forward;

11. Endorses the work plan for the feasibility study on the potential expansion of MPP’s
mandate to patented essential medicines, and requests management to report its
progress at the next meeting;

12. Approves the expansion MedsPaL to include data on medicines that are included in the
WHO EML and those that the EML committee have concluded offer a significant benefit
but have not been included in the 2017 EML due to cost implications. The MPP
management should request permission from the Swiss Agency for Development and
Cooperation to use the data collected in the course of the feasibility study and
subsequently inform the UNITAID secretariat;

13. Requests management to work with the Strategy and Partnerships Committee in
preparing its strategy for 2018-2022, to be presented at the next board meeting;

14. Requests MPP management to work closely with the Strategy and Partnerships
Committee to further refine and implement the MPP’s long term fundraising strategy.
This work should focus on protecting the current mandate while also looking towards
future opportunities. The approach should look at securing a continued relationship with
UNITAID, while at the same time seeking to create new, key strategic partnerships and
obtaining new sources of funding;

\(^1\) In the event of a tie in the decision making process, the Committee will refer the decision to the full Board for consideration
\(^2\) Introduction of a term limit of two years for committee members, renewable for one additional term
\(^3\) The value of acceptable gifts which do not need to be reported and extended gifts by Covered Members be CHF 100
15. Thanks the Expert Advisory Group for its report assessing the final results of the negotiations between the MPP and Pharco on a licence agreement for ravidasvir. The Board has reviewed the EAG report and the proposed licence agreement, and agrees with the EAG’s assessment that the proposed collaboration is consistent with the MPP’s mandate as outlined in its statutes and Memorandum of Understanding with UNITAID, and represents a significant improvement over the status quo. Therefore, the Board requests the Executive Director to finalize and sign the necessary documents with Pharco to formalize the collaboration;

16. Welcomes Dr. Marie-Paul Kieny as Chair elect from July 1st 2017 and to take on the Office of Chair of the Medicines Patent Pool Board effective from September 1st 2017, and appreciates the readiness of Dr. Sigrun Møgedal to continue in her position as Board Chair up to the end of August 2017 through the completion of the hand over period;

17. Adopts the Terms of Reference for the Strategy and Partnerships Committee and appoints Manica Balasegaram, Anna Zakowicz and Claudia Chamas as members of the committee;

18. Recommends the following changes to the Conflict of Interest declaration form:
   a. Inclusion of a clause in the declaration form, which acknowledges that the signatory has read and understood the Conflict of Interest Policy, Private Investments Policy, and Gifts Policy
   b. The definition of a “Related Person” in the declaration form be amended to include any domestic partner as opposed to spouse.